20 results on '"Shringarpure, Reshma"'
Search Results
2. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay
3. SAT-220-YI Efruxifermin treatment improved collagen biomarkers consistent with remodelling of the extracellular matrix in patients with F2-F3 fibrosis due to MASH
4. LBO-002 Efruxifermin significantly reduced liver fibrosis in MASH patients with F2-F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study)
5. FRI-512 - Characterization of the patterns of resolution of histopathology after efruxifermin treatment of patients with NASH fibrosis (F2/3) for 24 weeks
6. TOP-091 - Non-invasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in F2-F3 NASH patients: secondary analysis of Ph2b HARMONY study
7. GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH
8. Ubiquitin Conjugation Is Not Required for the Degradation of Oxidized Proteins by Proteasome.
9. Protein turnover by the proteasome in aging and disease1,2 <FN ID="FN1"><NO>1</NO>This article is part of a series of reviews on “Oxidatively Modified Proteins in Aging and Disease.” The full list of papers may be found on the homepage of the journal.Davies and Shringarpure are studying the mechanism by which the proteasome recognizes and degrades oxidatively damaged proteins, and how protein oxidation and proteolysis are affected by aging and disease.</FN> <FN ID="FN2"><NO>2</NO>Guest Editor: Earl Stadtman</FN>
10. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
11. Tu1393 Real-World use of Alosetron: Results of a Multi-Center Observational Study.
12. Tu1392 Psychological Variables Add Incremental Value to Biological Markers in Differentiating IBS From Healthy Volunteers.
13. Tu1386 Alosetron Treatment Reduced Health Care Utilization and Improved Symptoms More Effectively Than Traditional Therapy in Women With Severe IBS-D.
14. M1058 Alosetron is Associated With Improvements in Treatment Satisfaction and Quality of Life.
15. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
16. FRI066 - Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the regenerate trial.
17. LBP19 - Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non-invasive markers of fibrosis: results of a post hoc analysis from the interim analysis of the REGENERATE study.
18. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
19. AS075 - Obeticholic acid improves experimental non-invasive markers of non-alcoholic steatohepatitis and advanced fibrosis: a secondary analysis of the phase 3 regenerate study.
20. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.